Calidi Biotherapeutics, Inc. — Filing Summary
Important identity and period note: The supplied filing is First Light Acquisition Group, Inc.’s Form 10-K for the fiscal year ended December 31, 2022—not a 10-K filed by Calidi Biotherapeutics. FLAG was a blank-check SPAC with no operating business. Its proposed merger with Calidi was announced after year-end, on January 9, 2023.
Business context and reporting period
FLAG was formed to identify and combine with a business. The 2022 reporting period principally covered its search for a target, trust-account activity, and extension of its business-combination deadline. FLAG had no operating revenue. Its 2021 comparative results cover only March 24, 2021 (inception) through December 31, 2021, so they are not a full-year comparison.
Financial results and liquidity
| Metric | FY 2022 / Dec. 31, 2022 | Comparative period / Dec. 31, 2021 |
|---|---|---|
| Revenue | None; FLAG had not begun operations | None |
| Net income | $3.53 million | $3.39 million |
| Operating costs | $4.67 million | $1.78 million |
| Operating cash flow | $98,051 provided | $1.08 million used |
| Cash outside trust | $93,892 | $1.06 million |
| Trust-account securities | $42.45 million | $230.00 million |
| Working capital | $4.13 million deficit | Not stated here as a comparable measure |
| Total liabilities | $5.61 million | $16.45 million |
| Stockholders’ deficit | $5.21 million | $14.69 million |
- Net income was driven by non-operating items, especially a $6.72 million gain from the reduction in fair value of warrant liabilities and $1.63 million of trust-account earnings. These gains offset operating costs and $347,000 of income-tax provision; they do not represent operating-business profitability.
- During 2022, holders redeemed 18,871,976 Class A shares for approximately $190.01 million. At year-end, 4,128,024 redeemable public shares remained.
- FLAG reported $1.2575 million of principal drawn on related-party and other promissory notes. The balance sheet showed $1.225 million of promissory notes net of debt discount, plus $7,719 accrued interest and a $32,865 contingent-interest derivative liability. Some notes carried stated or contingent interest as high as 50%–100%.
- There was no long-term debt or off-balance-sheet financing arrangement reported. The $8.05 million deferred underwriting fee was waived in December 2022.
Material changes and proposed transaction
- The trust balance fell substantially following the September 2022 redemptions. FLAG also received extension funding of about $416,000 in connection with deadline extensions.
- On January 9, 2023, FLAG agreed to merge with Calidi, a clinical-stage biotechnology company developing cell-based delivery of oncolytic viruses. The stated Calidi equity value was $250 million, subject to adjustments, including net-debt and qualifying pre-closing milestone adjustments.
- A subsequent-events note described potential transaction proceeds of up to $82 million before expenses, comprising up to approximately $42 million in trust funds assuming no redemptions and a possible $40 million PIPE. The filing also says Franklin would not purchase the $50 million forward-purchase securities in connection with the Calidi transaction. The PIPE amount was described as possible, not assured.
- The merger was subject to stockholder approval and other closing conditions, including a minimum-cash condition and at least $5,000,001 of net tangible assets. The filing warns that high redemptions or insufficient financing could prevent closing or leave the combined company short of operating cash.
Outlook, risks, and unusual items
- Management and the auditor cited substantial doubt about FLAG’s ability to continue as a going concern. At year-end, FLAG had only $93,892 in operating cash and a $4.13 million working-capital deficit. Sponsor support for future working-capital loans was described as a commitment without a formal agreement.
- If FLAG did not complete a business combination by its applicable deadline, it would wind up and redeem public shares; warrants could expire worthless. The filing described a potential deadline as late as September 14, 2023 if available extensions were exercised.
- FLAG identified a material weakness in internal control over financial reporting involving derivative accounting and cash-flow statement presentation. Disclosure controls were deemed ineffective. Management described remediation efforts, but gave no assurance they would succeed; the identified errors did not trigger a restatement.
- Other key risks included sponsor and insider conflicts of interest, concentrated voting control, dilution, high-redemption risk, potential creditor claims against the trust, market and financing uncertainty, and sensitivity of reported earnings to warrant fair-value changes. The filing also discussed inflation, rising interest rates, COVID-19, and the Russia-Ukraine conflict.
- The merger consideration included potential milestone-linked shares: up to 18 million escalation shares tied to specified post-closing share-price targets over five years. The transaction also contemplated up to 2 million shares for non-redeeming FLAG public stockholders, subject to its terms.
Most important facts for investors to verify
- Confirm the correct issuer and filing: this is FLAG’s 2022 10-K, not Calidi’s operating-company annual report.
- Review the latest merger proxy/prospectus and subsequent filings for transaction status, closing conditions, minimum cash, actual PIPE commitments, redemption levels, and final cash available at closing.
- Reconcile trust-account cash and share redemptions against later extensions, deposits, taxes, fees, and any additional redemptions.
- Review the full debt and related-party-note terms, including interest, maturity, conversion rights, and amounts outstanding after year-end.
- Assess whether the material weakness was remediated and whether later filings report any further control deficiencies or corrections.
- Evaluate dilution from founder shares, warrants, merger consideration, escalation shares, and any financing securities, along with the combined company’s expected cash runway.